focus -WSS

focus

author：entertainment 2025-10-01 04:10:59 - browse：29636

WASHINGTON, DC - NOVEMBER 27: U.S. President Joe Biden speaks about supply chain resilience during an event in the Indian Treaty Room at the Eisenhower Executive Office Building on November 27, 2023 in Washington, DC. — President Biden spoke about supply chain resilience and drug shortages. Alex Wong/Getty Images

WASHINGTON — President Biden’s new plan to curb drug shortages by boosting domestic drug production won’t expand the supply of the chemotherapies that are currently in shortage, an administration official confirmed. The limited scope surprised experts, who told STAT Biden could have included those drugs in the effort.

The 15 cancer drugs in short supply account for only a little more than 10% of the drugs on FDA’s shortage list. But chemotherapies are far more crucial than many other drugs experiencing shortages, which include injections of amino acids and multivitamins, and sterile water. Gut-wrenching stories about cancer patients being switched to less-effective drugs have caused cancer doctors to agitate for government solutions.

Biden announced last week that he plans to use the Defense Production Act to get companies to make essential medicines and their ingredients in the United States. The administration will spend $35 million to boost domestic production of key starting materials for drugs that hospitals commonly use and are prone to shortages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

entertainment

leisure time

WSS

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Weight loss drugs should be covered by insurers, AMA says

Biotech reporter’s notebook: A sunnier mood at JPM 2024

What health policies could hitch a ride on a spending bill?

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

explore

focus

explore

Activists slam private health insurers over coverage restrictions

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Wildfire smoke exposes gaps in outdoor worker protections

Carbon Health diabetes program, a test of data

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

How one medical school became remarkably diverse

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

23andMe had bad news about my health. I wish a person had delivered it

What health policies could hitch a ride on a spending bill?

hotspot

Health and fitness trackers are measuring the wrong things

The SUPPORT Act is critical to fighting the opioid crisis

White House drug czar issues call for 'recovery

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Risky weight loss products often used by teens globally, per study

Generative AI mines health records to identify patients’ social needs

leisure time

entertainment

leisure time

hotspot